Novel biomarkers of nasopharyngeal carcinoma metastasis risk identified by reverse phase protein array based tumor profiling with consideration of plasma Epstein-Barr virus DNA load
PurposeIn patients with Epstein-Barr virus (EBV) associated nasopharyngeal carcinoma (NPC), intertumor heterogeneity causes interpatient heterogeneity in the risk of distant metastasis. We aimed to identify novel biomarkers of metastasis risk using reverse phase protein array (RPPA) profiling of NPC patients at risk for metastasis and considering plasma EBV DNA load. Experimental designA total of 98 patients with NPC with and without metastasis after treatment, matched with respect to clinical parameters, are enrolled. Total protein expression is measured by RPPA, and protein functions are analyzed by pathway bioinformatics. ResultsThe RPPA analysis revealed a profile of 70 proteins that are differentially expressed in metastatic and nonmetastatic tumors. Plasma EBV DNA load after treatment correlated with protein expression level better than plasma EBV DNA load before treatment did. The biomarkers of NPC metastasis identified by proteomics regulate signaling pathways involved in cell cycle progression, apoptosis, and epithelial-mesenchymal transition. The authors identified 26 biomarkers associated with 5-year distant failure-free survival in univariate analysis; five biomarkers remained significant in multivariate analysis. Conclusions and clinical relevanceA comprehensive RPPA profiling study is warranted to identify novel metastasis-related biomarkers and further examine the activation state of signaling proteins to improve estimation of metastasis risk for patients with EBV-associated NPC.
基金:
National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81372410, 81071837, 30670627, 81602392]; Special Fund Project for Technology Innovation of Foshan City [2014AG10003]; NIH/NCIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA016672]; Sister Institution Network Fund
语种:
外文
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类|3 区医学
小类|3 区生化研究方法
最新[2023]版:
大类|4 区生物学
小类|4 区生化研究方法
第一作者:
第一作者机构:[1]First Peoples Hosp Foshan, Dept Radiat Oncol Canc Ctr, Foshan P R, Peoples R China;[2]Sun Yat Sen Univ, Zhongshan Sch Med, Dept Pathophysiol, Guangzhou, Guangdong, Peoples R China;[3]Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA;
通讯作者:
通讯机构:[2]Sun Yat Sen Univ, Zhongshan Sch Med, Dept Pathophysiol, Guangzhou, Guangdong, Peoples R China;[3]Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA;[6]Univ Texas Grad Sch Biomed Sci Houston, Expt Therapeut Acad Program, Houston, TX USA;[7]Univ Texas Grad Sch Biomed Sci Houston, Canc Biol Program, Houston, TX USA;[9]Univ Texas MD Anderson Canc Ctr, Unit 1058, Dept Syst Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA
推荐引用方式(GB/T 7714):
Xu Tao,Su Bojin,Huang Peiyu,et al.Novel biomarkers of nasopharyngeal carcinoma metastasis risk identified by reverse phase protein array based tumor profiling with consideration of plasma Epstein-Barr virus DNA load[J].PROTEOMICS CLINICAL APPLICATIONS.2017,11(5-6):-.doi:10.1002/prca.201600090.
APA:
Xu, Tao,Su, Bojin,Huang, Peiyu,Wei, Weihong,Deng, Yanming...&Claret, Francois X..(2017).Novel biomarkers of nasopharyngeal carcinoma metastasis risk identified by reverse phase protein array based tumor profiling with consideration of plasma Epstein-Barr virus DNA load.PROTEOMICS CLINICAL APPLICATIONS,11,(5-6)
MLA:
Xu, Tao,et al."Novel biomarkers of nasopharyngeal carcinoma metastasis risk identified by reverse phase protein array based tumor profiling with consideration of plasma Epstein-Barr virus DNA load".PROTEOMICS CLINICAL APPLICATIONS 11..5-6(2017):-